Search results for "Pseudomonas Aeruginosa"

showing 10 items of 158 documents

A peptide from human β thymosin as a platform for the development of new anti-biofilm agents for Staphylococcus spp. and Pseudomonas aeruginosa

2016

Conventional antibiotics might fail in the treatment of biofilm-associated infections causing infection recurrence and chronicity. The search for antimicrobial peptides has been performed with the aim to discover novel anti-infective agents active on pathogens in both planktonic and biofilm associated forms. The fragment 9-19 of human thymosin β4 was studied through 1 μs MD simulation. Two main conformations of the peptide were detected, both constituted by a central hydrophobic core and by the presence of peripheral charged residues suggesting a possible mechanism of interaction with two models of biological membranes, related to eukaryotic or bacterial membrane respectively. In addition, …

Models Molecular0301 basic medicineStaphylococcus aureusPhysiology030106 microbiologyAntimicrobial peptidesSettore BIO/05 - ZoologiaPeptideMicrobial Sensitivity TestsMolecular Dynamics SimulationBiologymedicine.disease_causeSettore BIO/19 - Microbiologia GeneraleApplied Microbiology and BiotechnologyMicrobiologyStructure-Activity Relationship03 medical and health sciencesAnti-Infective AgentsmedicineHumansAmino Acid SequencePeptide sequencechemistry.chemical_classificationPseudomonas aeruginosaAntimicrobial peptides Molecular dynamics Staphylococcal biofilms ThymosinBiofilmThymosinGeneral MedicineAntimicrobialSettore CHIM/08 - Chimica FarmaceuticaThymosin030104 developmental biologychemistryBiochemistrySettore CHIM/03 - Chimica Generale E InorganicaBiofilmsPseudomonas aeruginosaPeptidesAntibacterial activityBiotechnology
researchProduct

An Experimental Toolbox for Structure‐Based Hit Discovery for P. aeruginosa FabF, a Promising Target for Antibiotics

2021

Abstract FabF (3‐oxoacyl‐[acyl‐carrier‐protein] synthase 2), which catalyses the rate limiting condensation reaction in the fatty acid synthesis II pathway, is an attractive target for new antibiotics. Here, we focus on FabF from P. aeruginosa (PaFabF) as antibiotics against this pathogen are urgently needed. To facilitate exploration of this target we have set up an experimental toolbox consisting of binding assays using bio‐layer interferometry (BLI) as well as saturation transfer difference (STD) and WaterLOGSY NMR in addition to robust conditions for structure determination. The suitability of the toolbox to support structure‐based design of FabF inhibitors was demonstrated through the …

Models MolecularBio-layer interferometrymedicine.drug_classAntibioticsMicrobial Sensitivity TestsCrystallography X-RayLigandsBiochemistryantibiotics3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseDrug Discoverymedicinebio-layer interferometryGeneral Pharmacology Toxicology and PharmaceuticsEnzyme InhibitorsPharmacologyligand-based NMRVirtual screeningBiological ProductsFull PaperMolecular StructureChemistryOrganic ChemistryLimitingFull Papersvirtual screeningCombinatorial chemistrystructure-based designAnti-Bacterial AgentsSaturation transferPseudomonas aeruginosaMolecular MedicineStructure basedChemmedchem
researchProduct

2015

Pseudomonas aeruginosa is a Gram-negative bacterium known to cause opportunistic infections in immune-compromised or immunosuppressed individuals that often prove fatal. New drugs to combat this organism are therefore sought after. To this end, we subjected the gene products of predicted perturbative genes to structure-based druggability predictions using DrugPred. Making this approach suitable for large-scale predictions required the introduction of new methods for calculation of descriptors, development of a workflow to identify suitable pockets in homologous proteins and establishment of criteria to obtain valid druggability predictions based on homologs. We were able to identify 29 pert…

MultidisciplinaryPseudomonas aeruginosaDrug discoveryDruggabilityComputational biologyProtein superfamilyBiologymedicine.disease_causechEMBLGenomeMicrobiologymedicineGeneOrganismPLOS ONE
researchProduct

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapene…

2020

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus

Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugAntibiotics
researchProduct

Antibacterial activity of Mediterranean Oyster mushrooms, species of genus Pleurotus (higher Basidiomycetes).

2013

Extracts of the Mediterranean culinary-medicinal Oyster mushrooms Pleurotus eryngii var. eryngii, P. eryngii var. ferulae, P. eryngii var. elaeoselini, and P. nebrodensis were tested for their in vitro growth inhibitory activity against a group of bacterial reference strains of medical relevance: Staphylococcus aureus ATCC 25923, S. epidermidis RP62A, Pseudomonas aeruginosa ATCC 15442, and Escherichia coli ATCC10536. All of the Pleurotus species analyzed inhibited the tested microorganisms in varying degrees. The data included in this paper for P. nebrodensis and P. eryngii var. elaeoselinii are new reports.

OysterMicroorganismStaphylococcusHuman pathogenmedicine.disease_causePleurotusApplied Microbiology and BiotechnologySpecies Specificitybiology.animalDrug DiscoveryBotanymedicineEscherichia coliPleurotus eryngiiFood scienceEscherichia coliPharmacologyPleurotusBiological Productsbiologybiology.organism_classificationAnti-Bacterial AgentsStaphylococcus aureusSettore BIO/03 - Botanica Ambientale E ApplicataPseudomonas aeruginosamedicinal mushrooms antibacterial activity Pleurotus human pathogensAntibacterial activityAgaricalesInternational journal of medicinal mushrooms
researchProduct

Propolis-Based Nanofiber Patches to Repair Corneal Microbial Keratitis

2021

In this research, polyvinyl-alcohol (PVA)/gelatin (GEL)/propolis (Ps) biocompatible nanofiber patches were fabricated via electrospinning technique. The controlled release of Propolis, surface wettability behaviors, antimicrobial activities against the S. aureus and P. aeruginosa, and biocompatibility properties with the mesenchymal stem cells (MSCs) were investigated in detail. By adding 0.5, 1, and 3 wt.% GEL into the 13 wt.% PVA, the morphological and mechanical results suggested that 13 wt.% PVA/0.5 wt.% GEL patch can be an ideal matrix for 3 and 5 wt.% propolis addition. Morphological results revealed that the diameters of the electrospun nanofiber patches were increased with GEL (from…

Pharmaceutical ScienceBiocompatible Materials02 engineering and technologyGelatinAnalytical ChemistryContact angleQD241-4410302 clinical medicineAnti-Infective AgentsSpectroscopy Fourier Transform InfraredDrug DiscoveryMesenchymal stem cell proliferationDrug CarriersChemistrySSCAFFOLDHYDROGELP<i>S. aureus</i>021001 nanoscience & nanotechnologyControlled releaseaeruginosaElectrospinningpropolisChemistry (miscellaneous)microbial keratitisPseudomonas aeruginosaBLINDNESSMolecular MedicineELECTROSPUN0210 nano-technologyStaphylococcus aureusfood.ingredient<i>P. aeruginosa</i>BiocompatibilitySurface PropertiesFABRICATIONMicrobial Sensitivity TestsCHEMICAL-COMPOSITIONaureusArticle03 medical and health sciencesfoodnanofibersPhysical and Theoretical Chemistrycorneal patchelectrospinningKeratitisCOMPOSITEGELATINOrganic ChemistryPropolisS. aureusDrug LiberationP. aeruginosaPolyvinyl AlcoholNanofiber030221 ophthalmology & optometryPROPERTYMEMBRANENuclear chemistry
researchProduct

Pseudomonas aeruginosa cause epidemic disease in the milkweed bug,Oncopeltus fasciatus dallas (Insecta, Heteroptera)

1976

Pseudomonas aeruginosa was recognized as the causative organism of an epidemic disease occurring in a laboratory breed ofOncopeltus fasciatus. The infection probably occurs peroral and is favoured by high temperature and humidity.Pseudomonas aeruginosa destroys the fat body of the bug.

PharmacologyFat bodybiologyPseudomonas aeruginosaHeteropteraCell Biologybiology.organism_classificationmedicine.disease_causeBreedMicrobiologyCellular and Molecular NeuroscienceCausative organismmedicineMolecular MedicineEpidemic diseaseMolecular BiologyExperientia
researchProduct

Meropenem Permeation through the Outer Membrane of &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; Can Involve Pathways Other than the OprD Porin Channel

1996

The outer membrane protein (OMP) OprD is the major channel through which carbapenems permeate the outer membrane of Pseudomonas aeruginosa. In this study, we analyzed the OMP profiles of several P. aeruginosa clinical isolates showing diminished susceptibility to imipenem while remaining susceptible to meropenem. All these isolates lacked OprD or showed a reduced expression of this porin. Susceptibility to meropenem was thus independent of the level of OprD expression, indicating that the antimicrobial could be taken up via an alternative route. The level of expression of OprC (70 kD) was also unrelated to meropenem susceptibility. Nevertheless, OMPs OprF and OprE were expressed by all isol…

PharmacologyImipenembiologyPseudomonas aeruginosaGeneral Medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationmedicine.disease_causeMeropenemPorinaMicrobiologyInfectious DiseasesOncologyDrug DiscoveryPorinpolycyclic compoundsmedicinebacteriaPharmacology (medical)Bacterial outer membranemedicine.drugPseudomonadaceaeAntibacterial agentChemotherapy
researchProduct

Acquisition of Class C β-Lactamase PAC-1 by Sequence Type 644 Strains of Pseudomonas aeruginosa

2019

Four sequence type 664 (ST664) (serotype O:5) strains of Pseudomonas aeruginosa that were highly resistant to antibiotics, including ceftolozane-tazobactam and ceftazidime-avibactam, but were susceptible to colistin were found to harbor the gene encoding the rare class C β-lactamase PAC-1 on a chromosomally located Tn 1721 -like transposon. The bla PAC-1 gene was associated with the 16S rRNA methylase determinant rmtF2 , which confers pan-aminoglycoside resistance.

PharmacologyTransposable elementSerotype0303 health sciencesLineage (genetic)030306 microbiologymedicine.drug_classPseudomonas aeruginosaAntibioticseducationBiologymedicine.disease_cause16S ribosomal RNA3. Good healthMicrobiology03 medical and health sciencesInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyColistinmedicinePharmacology (medical)Gene030304 developmental biologymedicine.drug
researchProduct

Carga y factores de riesgo para la neumonía adquirida en la comunidad de Pseudomonas aeruginosa : un estudio multinacional de prevalencia puntual de …

2018

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeru…

Pneumonia Pseudomonas aeruginosaMaleantibiotic resistanceInternationalityCross-sectional studybacterial colonizationvery elderlyPrevalenceDrug ResistanceDrug resistancePneumònia adquirida a la comunitatPseudomonas aeruginosa community acquired pneumoniaPulmonary Disease Chronic Obstructive0302 clinical medicineTracheostomyCommunity-acquired pneumoniaRisk FactorsEpidemiology80 and overPrevalenceMedicineCommunity-Acquired Infection030212 general & internal medicineAged 80 and overCross InfectionadultarticleBacterialMiddle AgedAntibiotic coverageBronchiectasisCommunity-Acquired Infectionshospital patientpriority journalrisk factorAged; Aged 80 and over; Bronchiectasis; Community-Acquired Infections; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Female; Humans; Internationality; Logistic Models; Male; Middle Aged; Pneumonia Bacterial; Prevalence; Pseudomonas aeruginosa; Pulmonary Disease Chronic Obstructive; Risk Factors; TracheostomyPseudomonas aeruginosaInfectious diseasesFemaleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveCommunity-acquired pneumoniaLogistic ModelAdmissionSettore MED/10 - Malattie Dell'Apparato Respiratoriochronic lung diseasePulmonary Disease03 medical and health sciencesBronchiectasiInternal medicinePseudomonasDrug Resistance BacterialPneumonia BacterialHumanscontrolled studyhumanAgedCross-Sectional StudieBronchiectasisbusiness.industryRisk Factorcommunity acquired pneumoniaPneumoniamedicine.diseaselogistic regression analysismajor clinical studyantibiotic sensitivityPneumoniahospital admissionCross-Sectional StudiesLogistic Models030228 respiratory systemmicrobiological examinationbusinesschronic obstructive lung disease
researchProduct